Alexandra B. Forman
YOU?
Author Swipe
View article: Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S3 Gene Sets
View article: Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplemental Figures S1-S6 and Legends
View article: Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S2 RNAseq
View article: The KAT module of the SAGA complex maintains the oncogenic gene expression program in <i>MYCN-</i> amplified neuroblastoma
The KAT module of the SAGA complex maintains the oncogenic gene expression program in <i>MYCN-</i> amplified neuroblastoma Open
Pediatric cancers are frequently driven by genomic alterations that result in aberrant transcription factor activity. Here, we used functional genomic screens to identify multiple genes within the transcriptional coactivator Spt-Ada-Gcn5-a…
View article: Supplementary Figure S5 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S5 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
Differential NXT2 expression in neuroblastoma cell lines
View article: Supplementary Table S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Table S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
CRISPR guide sequences
View article: Supplementary Figure S3 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S3 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 loss leads to loss of NXF1
View article: Supplementary Figure S3 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S3 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 loss leads to loss of NXF1
View article: Supplementary Figure S6 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S6 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 expression is not associated with neuroblastoma disease subtypes
View article: Supplementary Figure S5 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S5 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
Differential NXT2 expression in neuroblastoma cell lines
View article: Supplementary Figure S4 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S4 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 expression is associated with NXT1 dependency
View article: Supplementary Figure S2 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S2 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT1 is a selective and lethal dependency in neuroblastoma
View article: Supplementary Figure S4 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S4 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 expression is associated with NXT1 dependency
View article: Supplementary Table S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Table S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
CRISPR guide sequences
View article: Supplemental Figure S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplemental Figure S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
CRISPR screens prioritize rapidly lethal in vivo relevant dependencies
View article: Data from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Data from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited. An id…
View article: Supplementary Figure S6 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S6 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT2 expression is not associated with neuroblastoma disease subtypes
View article: Supplemental Figure S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplemental Figure S1 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
CRISPR screens prioritize rapidly lethal in vivo relevant dependencies
View article: Supplementary Figure S2 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Supplementary Figure S2 from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
NXT1 is a selective and lethal dependency in neuroblastoma
View article: Data from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer
Data from Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer Open
Cancer dependency maps, which use CRISPR/Cas9 depletion screens to profile the landscape of genetic dependencies in hundreds of cancer cell lines, have identified context-specific dependencies that could be therapeutically exploited. An id…
View article: Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S2 RNAseq
View article: Data from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Data from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies ar…
View article: Data from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Data from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single-agent MEK inhibitors is common, however, and combination therapies ar…
View article: Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S3 Gene Sets
View article: Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplemental Figures S1-S6 and Legends
View article: Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S1 STARS Scores
View article: Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S3 Gene Sets
View article: Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S2 RNAseq
View article: Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplemental Figures and Legends from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplemental Figures S1-S6 and Legends
View article: Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Open
Supplementary Table S1 STARS Scores